Cargando…

Ferric carboxymaltose vs. ferrous sulfate for the treatment of anemia in advanced chronic kidney disease: an observational retrospective study and cost analysis

In non-dialysis-dependent chronic kidney disease (NDD-CKD), erythropoiesis-stimulating agents (ESAs) and iron supplementation are essential for anemia management. Ferric carboxymaltose (FCM) is a relatively novel intravenous iron formulation used in different clinical settings, although scarce data...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cirillo, Luigi, Somma, Chiara, Allinovi, Marco, Bagalà, Alfredo, Ferro, Giuseppe, Di Marcantonio, Elio, Bellelli, Stefania, Dallari, Lorenzo Antonio, Ballo, Piercarlo, Dattolo, Pietro Claudio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018957/ https://www.ncbi.nlm.nih.gov/pubmed/33811227 http://dx.doi.org/10.1038/s41598-021-86769-z

Ejemplares similares

Efficacy and safety of ferric carboxymaltose versus ferrous sulfate for iron deficiency anemia during pregnancy: subgroup analysis of Korean women
por: Shim, Jae-Yoon, et al.
Publicado: (2018)

Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia
por: Friedrisch, João Ricardo, et al.
Publicado: (2015)

Ferric Carboxymaltose as Treatment in Women with Iron-Deficiency Anemia
por: Seid, Melvin H., et al.
Publicado: (2017)

Ferric carboxymaltose: A revolution in the treatment of postpartum anemia in Indian women
por: Rathod, Setu, et al.
Publicado: (2015)

Clinical experience with ferric carboxymaltose in the management of anemia in acute gastrointestinal bleeding
por: Ballester-Clau, Raquel, et al.
Publicado: (2019)

Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia: Letter to Editor
por: Kanshaiym, Sakiyeva, et al.
Publicado: (2020)

Efficacy of ferric carboxymaltose in iron deficiency anemia patients scheduled for pancreaticoduodenectomy
por: Park, Jangho, et al.
Publicado: (2023)

Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia
por: Calleja, José Luis, et al.
Publicado: (2015)

Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose
por: Toblli, Jorge Eduardo, et al.
Publicado: (2014)

Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy
por: Froessler, Bernd, et al.
Publicado: (2018)

Safety, pharmacokinetics, and pharmacodynamics of intravenous ferric carboxymaltose in children with iron deficiency anemia
por: Korczowski, Bartosz, et al.
Publicado: (2023)

Incidence of postpartum depression after treatment of postpartum anaemia with intravenous ferric carboxymaltose, intravenous ferric derisomaltose or oral ferrous sulphate: A randomized clinical trial
por: Bombač Tavčar, Lea, et al.
Publicado: (2023)

Intravenous ferric carboxymaltose for anaemia in pregnancy
por: Froessler, Bernd, et al.
Publicado: (2014)

Hypophosphatemia in children treated with ferric carboxymaltose
por: Posod, Anna, et al.
Publicado: (2020)

Ferric Carboxymaltose and Erythropoiesis-Stimulating Agent Treatment Reduces the Rate of Blood Transfusion in Refractory Anemia
por: Gidaro, Antonio, et al.
Publicado: (2022)

Assessing the costs and benefits of perioperative iron deficiency anemia management with ferric carboxymaltose in Germany
por: Froessler, Bernd, et al.
Publicado: (2018)

Iron Deficiency Anemia with Menorrhagia: Ferric Carboxymaltose a Safer Alternative to Blood Transfusion
por: Mishra, Vineet, et al.
Publicado: (2018)

Economic Evaluation of Ferric Carboxymaltose for the Management of Hemodialysis Patients with Iron Deficiency Anemia in Italy
por: Rognoni, Carla, et al.
Publicado: (2019)

Ferrous but not ferric iron sulfate kills photoreceptors and induces photoreceptor-dependent RPE autofluorescence
por: Shu, Wanting, et al.
Publicado: (2020)

MON-338 Severe Hypophosphatemia Induced by Intravenous Ferric Carboxymaltose Therapy for Iron Deficiency Anemia
por: Tam, Matthew, et al.
Publicado: (2020)

Ferric carboxymaltose for treatment of iron deficiency and iron deficiency anemia caused by abnormal uterine bleeding
por: Hagras, Ahmed M., et al.
Publicado: (2022)

Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose
por: Fang, Wendy, et al.
Publicado: (2019)

Intravenous ferric carboxymaltose versus oral ferrous sulfate replacement in elderly patients after acute non-variceal gastrointestinal bleeding (FIERCE): protocol of a multicentre, open-label, randomised controlled trial
por: Teutsch, Brigitta, et al.
Publicado: (2023)

Direct Comparison of the Safety and Efficacy of Ferric Carboxymaltose versus Iron Dextran in Patients with Iron Deficiency Anemia
por: Hussain, Iftikhar, et al.
Publicado: (2013)

Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial
por: Adkinson, N. Franklin, et al.
Publicado: (2018)

Treatment of anemia in cancer patients undergoing chemotherapy with intravenous ferric carboxymaltose without erythropoiesis-stimulating agents
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2020)

Successful Treatment of Iron Deficiency Anemia with Ferric Carboxymaltose in an Elderly Patient with Multiple Comorbidities and COVID-19
por: Bassi, Vincenzo, et al.
Publicado: (2021)

An Economic Analysis of Ferric Derisomaltose versus Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease in Norway, Sweden, and Finland
por: Pollock, Richard F, et al.
Publicado: (2021)

Ferric citrate and ferric EDTA but not ferrous sulfate drive amphiregulin-mediated activation of the MAP kinase ERK in gut epithelial cancer cells
por: Scheers, Nathalie M., et al.
Publicado: (2018)

Iron Bioavailability from Ferrous Ammonium Phosphate, Ferrous Sulfate, and Ferric Pyrophosphate in an Instant Milk Drink—A Stable Isotope Study in Children
por: Hurrell, Richard F., et al.
Publicado: (2022)

Cost-utility of ferric carboxymaltose (Ferinject®) for iron-deficiency anemia patients with chronic heart failure in South Korea
por: Lim, Eun-A, et al.
Publicado: (2014)

Comparison of ferric Carboxymaltose and iron sucrose complex for treatment of iron deficiency anemia in pregnancy- randomised controlled trial
por: Jose, Ambily, et al.
Publicado: (2019)

Improved Hemoglobin Response with Ferric Carboxymaltose in Patients with Gastrointestinal-Related Iron-Deficiency Anemia Versus Oral Iron
por: Lichtenstein, Gary R., et al.
Publicado: (2018)

Evaluation of Minimal Optimal Dose of Intravenous Ferric Carboxymaltose for Treatment of Iron Deficiency Anemia and Risk of Transient Hyperferritinemia
por: Alharbi, Ahmad A, et al.
Publicado: (2022)

Ferric carboxymaltose for anemia in Crohn’s disease patients at a tertiary center: A retrospective observational cohort study
por: Siqueira, Natália Souza Nunes, et al.
Publicado: (2023)

Patient-Reported Outcomes After Ferric Carboxymaltose Treatment for Iron Deficiency Anemia: A Prospective Observational Study
por: Kwong, Winghan J, et al.
Publicado: (2023)

Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency Anemia
por: Aktaş, Burak Yasin, et al.
Publicado: (2023)

Intravenous ferric carboxymaltose for the treatment of iron deficiency anaemia – reply
por: Cancado, Rodolfo Delfini, et al.
Publicado: (2020)

Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial
por: Howaldt, Stefanie, et al.
Publicado: (2021)

Paracoccidioides spp. ferrous and ferric iron assimilation pathways
por: Bailão, Elisa Flávia L. C., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_70mvppj4mkh6l03lp1atf33o1n